- Home
- PMEC vs APRE Comparison
PMEC vs APRE Comparison
Compare PMEC & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMEC | APRE |
|---|---|---|
| Founded | 1984 | 2006 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 6.9M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PMEC | APRE |
|---|---|---|
| Price | $1.07 | $0.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 17.3K | ★ 70.5K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $74,349,000.00 | $488,239.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $0.54 | $0.90 |
| 52 Week High | $2.44 | $5.00 |
Technical Indicators
Market Signals| Indicator | PMEC | APRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 34.26 |
| Support Level | $1.00 | $0.91 |
| Resistance Level | $1.08 | $1.14 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 63.64 | 16.67 |
Price Performance
Historical ComparisonAbout PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.